SLPI and liver dysplastic nodule: Recent advancements have introduced a variety of novel biomarkers, including protein-based biomarkers such as serum secreted leukocyte protease inhibitor (SLPI), which has proven to be a valuable predictor of DN progression (Sun et al., 2024).